Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07525947Phase 1Recruiting

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

Role: lead

NCT07533955Phase 1Not Yet Recruiting

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis

Role: lead

NCT07541287Phase 2Not Yet Recruiting

A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Role: lead

NCT07059312Phase 1Active Not Recruiting

A Phase 1 Study of JADE101 in Healthy Participants

Role: lead

All 4 trials loaded